These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 16048964

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C, Tremblay C, Giguel F, Chou TC, Hirsch MS.
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract] [Full Text] [Related]

  • 6. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
    J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro.
    Tremblay CL, Giguel F, Chou TC, Dong H, Takashima K, Hirsch MS.
    Antivir Ther; 2005 Feb; 10(8):967-8. PubMed ID: 16430202
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
    Klibanov OM, Williams SH, Iler CA.
    Curr Opin Investig Drugs; 2010 Aug; 11(8):940-50. PubMed ID: 20721836
    [Abstract] [Full Text] [Related]

  • 13. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G, Calvez V, Katlama C.
    Therapie; 2009 Aug; 64(1):9-16. PubMed ID: 19463248
    [Abstract] [Full Text] [Related]

  • 14. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY, He SY, Zhang ZJ, He LF, Chen XW, Teng T.
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
    [Abstract] [Full Text] [Related]

  • 15. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
    Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.
    Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
    [Abstract] [Full Text] [Related]

  • 16. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S.
    AIDS; 2006 Oct 24; 20(16):2065-73. PubMed ID: 17053352
    [Abstract] [Full Text] [Related]

  • 17. Prospects of HIV-1 entry inhibitors as novel therapeutics.
    Pierson TC, Doms RW, Pöhlmann S.
    Rev Med Virol; 2004 Oct 24; 14(4):255-70. PubMed ID: 15248253
    [Abstract] [Full Text] [Related]

  • 18. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
    Asin-Milan O, Sylla M, El-Far M, Belanger-Jasmin G, Haidara A, Blackburn J, Chamberland A, Tremblay CL.
    Antimicrob Agents Chemother; 2014 Dec 24; 58(12):7565-9. PubMed ID: 25267674
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.
    Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, Hirsch MS.
    Antimicrob Agents Chemother; 2002 May 24; 46(5):1336-9. PubMed ID: 11959565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.